MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
25 avr. 2024 08h00 HE
|
MediWound Ltd.
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the...
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
21 mars 2024 07h00 HE
|
MediWound Ltd.
$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42...
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
14 mars 2024 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12 févr. 2024 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of...
MediWound to Participate in Two Upcoming Investor Conferences
05 févr. 2024 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
09 janv. 2024 07h00 HE
|
MediWound Ltd.
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already approved for use for burn patients across all age...
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
28 déc. 2023 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
21 déc. 2023 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a...
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
21 nov. 2023 07h02 HE
|
MediWound Ltd.
NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission...
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
21 nov. 2023 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...